Methodology

A five-stage, pharmaceutical-grade pipeline.

Built from the systematic review used in drug development and regulatory submissions, pointed at the supplement shelf.

The pipeline was designed by a PhD in Medicinal Chemistry and Chemical Biology with a drug-discovery background, so each stage mirrors how a drug candidate is actually reviewed.

Research

Evidence audit from Cochrane reviews down to preclinical data, with a Tier A–F assignment. Mechanism of action, effective dose range from human clinical trials, absorption and bioavailability profile, and drug-interaction enzyme mapping.

Quality

GMP registry verification, third-party testing status, batch-specific certificate of analysis, contaminant risk by compound class, and regulatory history (FDA, EU RASFF, TGA).

Interactions

How the compound behaves alongside your other supplements or medications: absorption conflicts, CYP450 enzyme competition, and overlapping effects. Risk-stratified, with a timing schedule to separate them.

Compare

A unified evaluation integrating evidence + quality + interactions + cost. Real cost per verified effective daily dose, benchmarked against the market.

Verdict

A report with claim-level cited references and colour-coded conclusions: what to keep, what to drop, and what to buy instead. Every source is traceable.

Evidence tiers

Strong

Multiple meta-analyses, large N

Moderate

One meta-analysis or several RCTs

Preliminary

Small RCTs, N < 100

Hopium

Preclinical or surrogate only

Debunked

No effect or net harm

Verdict system

KEEP

Evidence-backed · dose verified

REPLACE

Better alternative exists

DROP

No clinical evidence · skip

Principles

No marketing claim passes unchallenged.

Lab markers are not health outcomes.

Certifications without registry verification are marketing.

Proprietary blends are assumed under-dosed.

Price is not a quality signal.

Monetisation is earned, not bought.

The gaps we close

The evidence gap

Lab results get marketed as clinical proof. We check whether human trials showed a real health benefit, not just a promising mechanism.

The quality gap

40% of label claim, wrong isomers, hidden doses. We verify against registries, not packaging.

The price gap

3–10× markup for identical bulk ingredients in premium branding. We benchmark real cost per effective dose.

The comparison gap

No transparent side-by-side exists. We rank competing products on evidence, quality, dose, and cost so you don't have to trust marketing.